LDK 378 - 1262982

Thu, 03/27/2014 - 23:20

Dear Drs

here's the Yahoo article about LDK 378.

http://news.yahoo.com/novartis-says-lung-cancer-patients-respond-drug-s…

It is unclear to me if this agent only worked for those with ALK mutation or all those with NSCLC. From the article (not scientific), it sounds like it has a positive impact on all NSCLC

thanks

ssflxl

Forums
Revision log message
Created by FeedsNodeProcessor

Dr West

Yes, it's very good news, but it's not really new information that ceritinib, or LDK378, has very significant activity against ALK-positive advanced NSCLC. Because it is an ALK inhibitor, there is far greater interest in its activity in the minority of patients with ALK-positive NSCLC than in a broad, molecularly unselected population. In fact, there is a growing movement (coming from such major groups as ASCO) to stop doing any trials of targeted therapies in molecularly unselected patients.

-Dr. West

Dr West

Yes, it's very good news, but it's not really new information that ceritinib, or LDK378, has very significant activity against ALK-positive advanced NSCLC. Because it is an ALK inhibitor, there is far greater interest in its activity in the minority of patients with ALK-positive NSCLC than in a broad, molecularly unselected population. In fact, there is a growing movement (coming from such major groups as ASCO) to stop doing any trials of targeted therapies in molecularly unselected patients.

-Dr. West